Hasman Andreas
Royal Pharmaceutical Society of Great Britain.
Med Law. 2008 Mar;27(1):83-93.
The paper is a reflection on some of the ethical issues relating to decisions on the availability of new drugs made by the British National Institute for Health and Clinical Excellence (NICE). It outlines the way in which the Institute and its advisory committees make decisions on the funding of new treatments by the National Health Service and discusses the proposition that the organisational structures and methods of the Institute give rise to an accountability problem. It is suggested that NICE should simplify the way decisions are made, take proactive steps to better inform the public about the advantages and limitations of its approach, and provide a clearer distinction between the Institute itself and the appeal panels, which consider objections to its decisions.
本文反思了与英国国家卫生与临床优化研究所（NICE）在新药可及性决策方面相关的一些伦理问题。它概述了该研究所及其咨询委员会就国民医疗服务体系对新疗法的资金投入做出决策的方式，并讨论了一种观点，即该研究所的组织结构和方法引发了问责问题。有人建议，NICE应简化决策方式，采取积极措施，让公众更好地了解其方法的优缺点，并在该研究所本身与审议对其决策的反对意见的上诉小组之间做出更明确的区分。
